Education
About Us
Working with TipRanks
Follow Us
Swedish Orphan Biovitrum AB (SE:SOBI)
:SOBI
RESEARCH TOOLSreports
SOBI Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr241.80 - kr354.40
Previous CloseN/A
Volume57.50K
Average Volume (3M)379.46K
Market Cap
kr86.86B
Enterprise Valuekr125.76B
Total Cash (Recent Filing)kr1.14B
Total Debt (Recent Filing)kr16.73B
Price to Earnings (P/E)22.4
Beta0.87
Next Earnings
Apr 29, 2025EPS Estimate
2.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.07
Shares Outstanding356,000,060
10 Day Avg. Volume430,312
30 Day Avg. Volume379,456
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr350.00Price Target Upside25.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Swedish Orphan Biovitrum AB News
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?
PremiumPre-Earnings
Is 0MTD a Buy, Before Earnings?---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
3.43%
Mutual Funds
― Other Institutional Investors
91.93% Public Companies and
Individual Investors
SOBI FAQ
What was Swedish Orphan Biovitrum AB’s price range in the past 12 months?
Swedish Orphan Biovitrum AB lowest stock price was kr241.80 and its highest was kr354.40 in the past 12 months.
What is Swedish Orphan Biovitrum AB’s market cap?
Swedish Orphan Biovitrum AB’s market cap is kr86.86B.
When is Swedish Orphan Biovitrum AB’s upcoming earnings report date?
Swedish Orphan Biovitrum AB’s upcoming earnings report date is Apr 29, 2025 which is today.
How were Swedish Orphan Biovitrum AB’s earnings last quarter?
Swedish Orphan Biovitrum AB released its earnings results on Feb 05, 2025. The company reported kr4.07 earnings per share for the quarter, beating the consensus estimate of kr3.592 by kr0.478.
Is Swedish Orphan Biovitrum AB overvalued?
According to Wall Street analysts Swedish Orphan Biovitrum AB’s price is currently Undervalued.
Does Swedish Orphan Biovitrum AB pay dividends?
Swedish Orphan Biovitrum AB does not currently pay dividends.
What is Swedish Orphan Biovitrum AB’s EPS estimate?
Swedish Orphan Biovitrum AB’s EPS estimate is 2.24.
How many shares outstanding does Swedish Orphan Biovitrum AB have?
Swedish Orphan Biovitrum AB has 356,000,060 shares outstanding.
What happened to Swedish Orphan Biovitrum AB’s price movement after its last earnings report?
Swedish Orphan Biovitrum AB reported an EPS of kr4.07 in its last earnings report, beating expectations of kr3.592. Following the earnings report the stock price went down -0.244%.
Which hedge fund is a major shareholder of Swedish Orphan Biovitrum AB?
Currently, no hedge funds are holding shares in SE:SOBI
---
Company Description
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hemophilia, immunology, and hereditary conditions. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement development programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi recently acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition).
---
SOBI Stock 12 Month Forecast
Average Price Target
kr350.00
▲(25.36% Upside)
Technical Analysis
---